CORK, Ireland, January 7, 2016 /PRNewswire/ — Results from ongoing phase IIb Week 32 study show that if successfully developed and approved, people living with HIV could potentially maintain viral suppression Janssen Sciences Ireland UC (Janssen), today formalized its collaboration with ViiV Healthcare on phase III development and commercialization of …